The efficacy and safety of stereotactic body radiotherapy combined with systematic therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis

Abstract

There is considerable interest in the potential of stereotactic body radiation therapy (SBRT) combined with systemic therapy such as tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs). However, its efficacy and safety remain unclear. The purpose of this study was to evaluate the efficacy and safety of conducting SBRT during ICI or TKI treatment in different disease settings for patients with metastatic renal cell carcinoma (mRCC). A total of 16 studies were ultimately included. Under the random effects model, the pooled 1-year local control rate (1-yr LCR) and objective response rate (ORR) were 90% (95% confidence interval [CI]: 80%–95%, I² = 67%) and 52% (95% CI: 37%–67%, I² = 90%), respectively. SBRT concomitant with different systemic therapy yield significant different 1-yr LCR (p < 0.01) and ORR (p = 0.02). Regarding survival benefits, the pooled 1-year progression-free survival (1-yr PFS) and 1-year overall survival (1-yr OS) rates were 45% (95% CI: 29%–62%, I² = 91%) and 85% (95% CI: 76%–91%, I² = 66%), respectively. 1-yr PFS and 1-yr OS in different disease settings demonstrated significant difference (p < 0.01). As for toxicity, the pooled incidence of grade 3–4 adverse events was 14% (95% CI: 5%–26%, I² = 90%). This study highlights the feasibility of utilizing these strategies in mRCC patients, especially those with a low metastatic tumor burden.

Keywords

metastatic renal cell carcinoma / stereotactic body radiation therapy (SBRT) / systemic therapy

References

1	H Sung, J Ferlay, RL Siegel, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:
2	L Bukavina, K Bensalah, F Bray, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529-542. doi:
3	K Gupta, JD Miller, JZ Li, MW Russell, C Charbonneau. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193-205. doi:
4	S Siva, G Kothari, A Muacevic, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol. 2017;14(9):549-563. doi:
5	M Stenman, G Sinclair, P Paavola, P Wers?ll, U Harmenberg, M Lindskog. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014. Radiother Oncol. 2018;127(3):501-506. doi:
6	NG Zaorsky, EJ Lehrer, G Kothari, AV Louie, S Siva. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515-523. doi:
7	GK Hunter, EH Balagamwala, SA Koyfman, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol. 2012;2(4):e95-e100. doi:
8	JA Miller, EH Balagamwala, L Angelov, et al. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. J Neurosurg Spine. 2016;25(6):766-774. doi:
9	K De Wolf, S Rottey, K Vermaelen, et al. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol. 2017;12(1):157. doi:
10	N Dengina, T Mitin, S Gamayunov, S Safina, Y Kreinina, I Tsimafeyeu. Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study. ESMO Open. 2019;4(5):e000535. doi:
11	V Gebbia, A Girlando, A DIG, et al. Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world. Anticancer Res. 2020;40(12):7037-7043. doi:
12	P Cheung, S Patel, SA North, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol. 2021;80(6):693-700. doi:
13	C Franzese, G Marvaso, G Francolini, et al. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis. 2021;38(6):527-537. doi:
14	SGC Kroeze, C Fritz, J Schaule, et al. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int. 2021;127(6):703-711. doi:
15	Y Liu, Z Zhang, R Liu, et al. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiat Oncol. 2021;16(1):211. doi:
16	R Hannan, M Christensen, H Hammers, et al. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol. 2022;5(2):216-224. doi:
17	W Li, Z Cao, P Chang, B Zhang, F Li, D Chang. Clinical efficacy of PD-1 inhibitors plus split-course radiotherapy in the first-line treatment of advanced kidney cancer: a randomized controlled trial. J Oncol. 2022;2022:8100323. doi:
18	M-W Ma, H-Z Li, X-S Gao, et al. Outcomes of high-dose stereotactic ablative radiotherapy to all/multiple sites for oligometastatic renal cell cancer patients. Curr Oncol. 2022;29(10):7832-7841. doi:
19	C Masini, C Iotti, U De Giorgi, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur Urol. 2022;81(3):274-282. doi:
20	S Siva, M Bressel, ST Wood, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma—the RAPPORT trial. Eur Urol. 2022;81(4):364-372. doi:
21	C Onal, E Oymak, OC Guler, et al. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. Strahlenther Onkol. 2023;199(5):456-464. doi:
22	G Ingrosso, C Becherini, G Francolini, et al. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: a systematic review. Crit Rev Oncol Hematol. 2021;159:103242. doi:
23	RJ Motzer, C Porta, M Eto, et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2023;41(suppl 16):4502. doi:
24	BI Rini, ER Plimack, V Stus, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma. J Clin Oncol. 2023;41(suppl 17). doi:
25	MH Tsai, JA Cook, GV Chandramouli, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007;67(8):3845-3852. doi:
26	S Siva, MP MacManus, RF Martin, OA Martin. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82-90. doi:
27	EJ Lehrer, R Singh, M Wang, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021;7(1):92-106. doi:
28	SGC Kroeze, M Pavic, K Stellamans, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24(3):e121-e132. doi:
29	PH Patel, D Palma, F McDonald, AC Tree. The Dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol). 2019;31(12):824-833. doi:
30	CM Lanier, E McTyre, M LeCompte, et al. The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: results of a large single institution retrospective analysis. Clin Neurol Neurosurg. 2018;165: 24-28. doi:
31	MJ Page, JE McKenzie, PM Bossuyt, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:
32	T Knoll, MI Omar, S Maclennan, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur Urol. 2018;73(2):290-300. doi:
33	RR Weichselbaum, S Hellman. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378-382. doi:
34	J Lau, JP Ioannidis, CH Schmid. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826. doi:
35	M Egger, G Davey Smith, M Schneider, C Minder. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi: